# Ifezuntirgene inilparvovec PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec

> The PDUFA target action date for ifezuntirgene inilparvovec, sponsored by uniQure N.V. (QURE), is May 1, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ifezuntirgene inilparvovec PDUFA date?

The PDUFA target action date for ifezuntirgene inilparvovec, sponsored by uniQure N.V. (QURE), is May 1, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~" Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-122362, https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ifezuntirgene inilparvovec |
| Codes | AMT-130 |
| Sponsor | uniQure N.V. (QURE) https://sec-api.dev/companies/qure/catalysts |
| Indications | huntington's disease, severe medical needs, today |
| Modality | gene_therapy |
| FDA designations | accelerated, breakthrough, fast track, orphan, priority review, rmat |

## Timeline

### Q2 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-02-27, last confirmed 2025-02-27.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001693): "After the completion of these interactions, the Company expects to provide a regulatory update in the second quarter of 2025, including the expected timing of a potential BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001693): "Examples of these forward-looking statements include, but are not limited to, statements concerning the Company's cash runway and its ability to fund its operations into the second half of 2027 and the planned use of proceeds from its first quarter 2025 public offering; the Company's plans for further interactions with the FDA to discuss the requirements for its planned BLA submission for AMT-130; the Company's ability to utilize an accelerated pathway to progress AMT-130 through regulatory approval; the" https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001693): "The Company has scheduled a Type B meeting with the FDA in the first quarter of 2025 to discuss chemistry, manufacturing and control (CMC) requirements to support its planned BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm

### September 24, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-06-02, last confirmed 2026-07-29.
- SEC Form 8-K (accession 0001104659-25-092740): "On September 24, 2025, the Company announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-092740): "Lexington, MA and Amsterdam, the Netherlands, September 24, 2025 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-021890): "In September 2025, the Company announced positive topline data from the pivotal Phase I/II study for AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021890/qure-20260302xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-108802): "In September 2025, the Company announced positive topline data from the pivotal Phase I/II study for AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465925108802/qure-20251110xex99d1.htm
- SEC prospectus (424B) (accession 0001104659-25-093983): "On September 24, 2025, we announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465925093983/tm2526258-2_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-087815): "In September 2025, we announced positive topline data from the three-year analysis of cohorts one and two of the ongoing Phase I/II studies of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465926087815/qure-20260630x10q.htm
- SEC prospectus (424B) (accession 0001104659-26-077336): "In September 2025, we announced positive topline data from the three-year analysis of the ongoing Phase I/II studies of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465926077336/tm2618428-2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-076466): "In September 2025, we announced positive topline data from the three-year analysis of the ongoing Phase I/II studies of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465926076466/tm2618428-1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-055250): "In September 2025, we announced positive topline data from the three-year analysis of the ongoing Phase I/II studies of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465926055250/qure-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-021898): "In September 2025, we announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-021898): "In September 2025, we announced positive topline data from the pivotal Phase I/II study of AMT-130." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-021898): "In September 2025, we announced positive topline data from the pivotal Phase I/II study of AMT-130 in which we analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high-dose; n=12 low-dose) of which 12 patients per dose group had attained 36 months of follow-up as of the June 30, 2025 cutoff date." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm

### November 3, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Stage: 1/2.
- First seen 2025-12-04, last confirmed 2025-12-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-118292): "In the final meeting minutes, and consistent with uniQure's November 3, 2025 press release, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission. uniQure is carefully evaluating the feedback and plans to urgently request a follow-up meeting with the FDA to take place in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465925118292/qure-20251204xex99d1.htm

### Dec 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2026-03-02, last confirmed 2026-07-29.
- SEC Form 10-Q (accession 0001104659-26-087815): "In December 2025, we announced that in the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 were currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926087815/qure-20260630x10q.htm
- SEC prospectus (424B) (accession 0001104659-26-077336): "In December 2025, we announced that in the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926077336/tm2618428-2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-076466): "In December 2025, we announced that in the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926076466/tm2618428-1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-055250): "In December 2025, we announced that in the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926055250/qure-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-021898): "In December 2025, we announced that in the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-021898): "However, in December 2025, we announced that in the final meetings minutes from the pre-BLA meeting with the FDA held in October 2025, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-021898): "In December 2025, we announced that the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-021898): "In particular, in December 2025 we announced that the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-021898): "However, in December 2025 we announced that the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission." https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm

### Q1 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-07-29, last confirmed 2025-09-24.
- SEC Form 8-K (accession 0001104659-25-092740): "The Company plans to discuss the AMT-130 data with the FDA at a pre-BLA meeting expected later this year, with the intention of submitting a BLA in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924x8k.htm
- SEC Form 8-K (accession 0001104659-25-092740): "Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company's plans to explore AMT-130 in a fourth cohort of up to 6 patients with lower striatal volumes compared to those patients enrolled in previous cohorts; the Company's plans to have a pre-BLA meeting with the FDA later this year, and the Company's plans to submit a BLA for AMT-130 in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-092740): "Examples of these forward-looking statements include, but are not limited to, statements concerning: the potential clinical and functional effects of AMT-130; the Company's belief that AMT-130 has the potential to transform the Huntington's disease treatment landscape; the timing and outcome of regulatory interactions with respect to the AMT-130 program, including the Company's expected pre-BLA meeting later this year and timing of the Company's planned BLA submission in the first quarter of 2026; and the Company's potential U.S. launch of AMT-130 in 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009692): "~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;" https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-092740): "~ uniQure plans to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval ~" https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-092740): "We are eager to discuss the data with the FDA at our pre-BLA meeting expected later this year, with the goal of submitting a BLA in the first quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924xex99d1.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-06-17, last confirmed 2026-07-29.
- SEC prospectus (424B) (accession 0001104659-26-077336): "On June 17, 2026, we announced our plan to submit a BLA for AMT-130 in Huntington's disease during the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465926077336/tm2618428-2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-076466): "On June 17, 2026, we announced our plan to submit a BLA for AMT-130 in Huntington's disease during the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465926076466/tm2618428-1_424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-087808): "Discussions with the FDA to align on the confirmatory study design and analysis are underway and the Company expects to submit a BLA in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-074853): "~ Company intends to submit the BLA in third quarter of 2026 ~" https://www.sec.gov/Archives/edgar/data/1590560/000110465926074853/tm2618105d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-074853): "The Company intends to submit the BLA in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1590560/000110465926074853/tm2618105d1_ex99-1.htm

### Aug 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001104659-26-122367): "We submitted our BLA for ifezuntirgene inilparvovec to the FDA in August 2026 and the FDA accepted the application for review in October 2026, with a PDUFA target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm

### Sep 2026: topline data readout

- Status: scheduled. Date confidence: month. Stage: 1/2.
- First seen 2026-07-29, last confirmed 2026-07-29.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-087808): "~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~" https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729xex99d1.htm

### November 2, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-11-02, last confirmed 2026-11-04.
- SEC Form 8-K (accession 0001104659-26-120915): "November 2, 2026, uniQure N.V. (the "Company") issued a press release announcing the U.S. Food and Drug Administration ("FDA") has accepted for review the Biologics License Application ("BLA") for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington's disease submitted under the Accelerated Approval pathway." https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm
- SEC Form 8-K (accession 0001104659-26-120915): "November 2, 2026, the Company announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington's disease submitted under the Accelerated Approval pathway." https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-120915): "Lexington, MA and Amsterdam, the Netherlands, November 2, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington's disease submitted under the Accelerated Approval pathway." https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-122367): "On November 2 2026, we announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway." https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm

### May 1, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-02, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122362): "~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~" https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-122367): "We submitted our BLA for ifezuntirgene inilparvovec to the FDA in August 2026 and the FDA accepted the application for review in October 2026, with a PDUFA target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122362): "The BLA was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-26-120915): "The application has been granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-120915): "The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-120915): "~ FDA sets PDUFA target action date of May 1, 2027 ~" https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-122367): "The application has been granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of May 1, 2027." https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm

## Same indication

- [Brezosiran](https://sec-api.dev/pdufa/brezosiran) (ALNY)
- [Epilepsy](https://sec-api.dev/pdufa/epilepsy) (QURE)

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ifezuntirgene inilparvovec PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec

```bibtex
@misc{secapidev_pdufa_ifezuntirgene_inilparvovec_20261116,
  title        = {Ifezuntirgene inilparvovec PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ifezuntirgene_inilparvovec_20261116","title":"Ifezuntirgene inilparvovec PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
